Botensilimab

Monoclonal antibody

Also known as AGEN1181

Stoppedregistry status

Evidence outlook

Phase 3 study terminated; a Phase 2 study is active

The furthest-phase study registered for this program (NCT07152821) was terminated, and no Phase 3 study is active; a Phase 2 study is active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.

Also in development:Non-Small Cell Lung Cancer · Phase 2

Featured evidence outside this drug's tracked markets:CIME (NCT06346197) · Gastric Cancer · Phase 3 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Colorectal Cancer
Other / comorbidity
NCT06346197 · Centre Leon Berard
2025-12-08 – 2028-05-15 · Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06279130 · The Netherlands Cancer Institute
2024-01-29 – 2034-01-29 · Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
What this study did
Phase 2 (25)
Colorectal Cancer
NCT07227636 · Memorial Sloan Kettering Cancer Center
2025-11-07 – 2030-11 · Colorectal Cancer, Rectal Cancer
What this study did
NCT05608044 · Agenus Inc.
2022-11-30 – 2029-09 · Metastatic Colorectal Cancer
What this study did
NCT07551596 · National Cancer Institute (NCI)
2027-05-25 – 2029-08-28 · Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
What this study did
NCT07595874 · City of Hope Medical Center
2026-07-01 – 2028-12-16 · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
What this study did
NCT07550088 · Darren Sigal, MD
2026-06-10 – 2028-12 · Colorectal Cancer Metastatic
What this study did
NCT06268015 · Nicholas DeVito, MD
2024-11-18 – 2028-07 · Colorectal Cancer
What this study did
NCT05845450 · Gruppo Oncologico del Nord-Ovest
2023-05-11 – 2028-05 · Colorectal Cancer, Resectable Colorectal Carcinoma
What this study did
NCT06300463 · Weill Medical College of Cornell University
2024-03-26 – 2027-12 · Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
What this study did
NCT06589440 · Stingray Therapeutics
2024-11-20 – 2027-07-31 · Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
What this study did
NCT06575725 · City of Hope Medical Center
2024-11-01 – 2027-01-28 · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
What this study did
NCT05571293 · Weill Medical College of Cornell University
2023-03-17 – 2024-11-14 · Colorectal Neoplasms
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07735624 · Dana-Farber Cancer Institute
2026-08-10 – 2032-12-31 · Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
What this study did
NCT05864534 · Northwestern University
2024-01-19 – 2031-08-31 · Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
What this study did
NCT06843551 · Benjamin Spieler
2025-06-18 – 2030-08-01 · Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
What this study did
NCT07578337 · Nelum Corp
2026-07-15 – 2029-02-28 · Untreated, Advanced Pancreatic Cancer
What this study did
NCT07516366 · National Cancer Institute (NCI)
2027-05-17 – 2028-12-31 · Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT06843434 · Memorial Sloan Kettering Cancer Center
2025-02-20 – 2028-02-20 · Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
What this study did
NCT04028063 · University of Colorado, Denver
2020-01-28 – 2027-12-31 · Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
What this study did
NCT05928806 · Michael B. Atkins, MD
2023-09-25 – 2027-11-10 · Advanced Renal Cell Carcinoma
What this study did
NCT06780787 · City of Hope Medical Center
2025-05-20 – 2027-11-05 · Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
What this study did
NCT06251973 · Memorial Sloan Kettering Cancer Center
2024-02-01 – 2027-08-01 · Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05632328 · Bruno Bockorny
2024-08-08 – 2027-04-01 · Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
What this study did
NCT05529316 · Agenus Inc.
2022-12-12 – 2026-04-27 · Advanced Melanoma
What this study did
NCT05630183 · Agenus Inc.
2023-03-27 – 2026-01-05 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
Phase 1/2 (2)
Colorectal Cancer
NCT05627635 · City of Hope Medical Center
2023-05-03 – 2027-06-16 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
What this study did
NCT05672316 · City of Hope Medical Center
2023-05-11 – 2026-12-01 · Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
What this study did
Phase 1 (8)
Colorectal Cancer
NCT06411691 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-11-04 – 2030-11-01 · Colorectal Cancer, Pancreatic Cancer
What this study did
NCT07193862 · Northwell Health
2025-12-10 – 2028-04-15 · Colorectal Cancer Metastatic
What this study did
NCT06336902 · University of Southern California
2025-01-15 – 2028-01-15 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
What this study did
NCT07128355 · Massachusetts General Hospital
2026-05-12 – 2027-09 · Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06076837 · HonorHealth Research Institute
2025-01-09 – 2025-12-22 · Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
What this study did
NCT05377528 · Agenus Inc.
2022-07-19 – 2024-12-23 · Advanced Solid Tumor
What this study did
NCT04121676 · Agenus Inc.
2019-09-26 – 2024-11-30 · Advanced Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Botensilimab: this drugPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Botensilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06300463 · CT.gov ↗
What to watch
2027 (10)
January 2027 (2)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-01-01 · NCT07128355 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-01-15 · NCT06336902 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue SarcomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04028063 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT07735624 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerActive not recruiting
Est. primary completion 2027-06-16 · NCT05627635 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-07-31 · NCT06589440 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer …Active not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-09 · NCT05608044 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Recruiting
Est. primary completion 2027-11-05 · NCT06780787 · CT.gov ↗
What to watch
2028 (7)
February 2028 (1)
Phase 2Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal AdenocarcinomaRecruiting
Est. primary completion 2028-02-20 · NCT06843434 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-04-15 · NCT07193862 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastric Cancer, MSI-H, Metastatic Cancer, Advanced CancerRecruiting
Est. primary completion 2028-05-15 · NCT06346197 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2028-07 · NCT06268015 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-09 · NCT07550088 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-12-16 · NCT07595874 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8Recruiting
Est. primary completion 2028-12-31 · NCT07516366 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2/3Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid TumorsRecruiting
Est. primary completion 2029-01-29 · NCT06279130 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Untreated, Advanced Pancreatic CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07578337 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-08-28 · NCT07551596 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2029-11-01 · NCT06411691 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04 · NCT06322108 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2030-08-01 · NCT06843551 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-11 · NCT07227636 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma MultiformeActive not recruiting
Est. primary completion 2031-07-31 · NCT05864534 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026ApprovalArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗